Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer

[1]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[2]  Fachao Zhi,et al.  Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice , 2020, Theranostics.

[3]  Noam Shental,et al.  The human tumor microbiome is composed of tumor type–specific intracellular bacteria , 2020, Science.

[4]  V. Heinemann,et al.  Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study , 2020, British Journal of Cancer.

[5]  Jessica K. Lang,et al.  Expression of FFAR2 by Dendritic Cells Prevents Their Expression of IL27 and is Required For Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice. , 2020, Gastroenterology.

[6]  Xiao-shuang Liu,et al.  Critical Role of Toll-Like Receptor 4 (TLR4) in Dextran Sulfate Sodium (DSS)-Induced Intestinal Injury and Repair. , 2019, Toxicology letters.

[7]  Myung Ah Lee,et al.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[8]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[9]  Wenchuan Wu,et al.  Cell-intrinsic PD-1 Promotes Proliferation in Pancreatic Cancer by Targeting CYR61/CTGF via the Hippo Pathway. , 2019, Cancer letters.

[10]  N. Wages,et al.  A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients , 2019, Journal of Immunotherapy for Cancer.

[11]  J. D'haese,et al.  Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer , 2019, Cancers.

[12]  Wei Wang,et al.  Toll-Like Receptor 4 (TLR4)/Cyclooxygenase-2 (COX-2) Regulates Prostate Cancer Cell Proliferation, Migration, and Invasion by NF-κB Activation , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[13]  Lingjin Huang,et al.  Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression , 2018, BMC Cancer.

[14]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[15]  G. Weiss,et al.  A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus) , 2017, British Journal of Cancer.

[16]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[17]  T. Gajewski,et al.  Innate immune signaling and regulation in cancer immunotherapy , 2016, Cell Research.

[18]  V. Kraus,et al.  Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. , 2016, Osteoarthritis and cartilage.

[19]  J. Logomarsino,et al.  Bacterial Lipopolysaccharide, Lipopolysaccharide-Binding Protein, and Other Inflammatory Markers in Obesity and After Bariatric Surgery. , 2016, Metabolic syndrome and related disorders.

[20]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[21]  M. Atkins,et al.  Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC , 2016, Cancer Immunology Research.

[22]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[23]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[24]  H. Tilg,et al.  Microbiota and diabetes: an evolving relationship , 2014, Gut.

[25]  V. Mohan,et al.  Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes , 2014, Molecular and Cellular Biochemistry.

[26]  Nan Li,et al.  TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells , 2013, Cellular and Molecular Immunology.

[27]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[28]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[29]  N. Yusuf,et al.  Cell mediated immune responses through TLR4 prevents DMBA‐induced mammary carcinogenesis in mice , 2012, International journal of cancer.

[30]  Yuan Tian,et al.  Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. , 2010, World journal of gastroenterology.

[31]  Xiaoyuan Wang,et al.  Lipopolysaccharide: Biosynthetic pathway and structure modification. , 2010, Progress in lipid research.

[32]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[33]  C. Elmets,et al.  Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. , 2008, Cancer research.

[34]  Stephen R. Clark,et al.  Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood , 2007, Nature Medicine.

[35]  I. Chaudry,et al.  17Beta-estradiol downregulates Kupffer cell TLR4-dependent p38 MAPK pathway and normalizes inflammatory cytokine production following trauma-hemorrhage. , 2007, Molecular immunology.

[36]  S Kumar,et al.  Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[37]  S. Akira,et al.  Toll-like receptors and innate immunity , 2006, Journal of Molecular Medicine.

[38]  N. Sheerin,et al.  Toll‐like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products , 2006, Clinical and experimental immunology.

[39]  A. Malkinson,et al.  Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. , 2005, Journal of the National Cancer Institute.

[40]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[41]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[42]  Ruslan Medzhitov,et al.  Toll-like receptors and innate immunity , 2001, Nature Reviews Immunology.

[43]  N. Mackman,et al.  LPS induction of gene expression in human monocytes. , 2001, Cellular signalling.

[44]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[45]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[46]  R. Ulevitch,et al.  Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum , 1986, The Journal of experimental medicine.

[47]  Jessica K. Lang,et al.  Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice , 2020 .

[48]  Michael Karin,et al.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. , 2005, The Journal of clinical investigation.